Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling

1. Yofe, I.
2. Landsberger, T.
3. Yalin, A.
4. Solomon, I.
5. Costoya, C.
6. Demane, D.F.
7. Shah, M.
8. David, E.
9. Borenstein, C.
10. Barboy, O.
11. Matos, I.
12. Peggs, K.S.
13. Quezada, S.A.
14. Amit, I.